Semaglutide: Play An Important Role In Global Weight Loss Market-www.china-sinoway.com

Semaglutide: Play an important role in Global Weight Loss Market

Sep 04, 2024

Semaglutide, a GLP-1 receptor agonist, is revolutionizing the management of type 2 diabetes and weight loss. It's available in injectable and oral forms, marketed as Ozempic, Rybelsus for diabetes, and Wegovy for weight reduction.

In medical applications, it enhances blood sugar control and aids in weight management for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have weight-related health issues. The FDA's 2024 approval also covers its use in reducing cardiovascular risks.

Clinical trials have shown that semaglutide can lead to significant weight loss, outperforming previous anti-obesity medications, although it's less effective than bariatric surgery. While long-term use may pose risks such as nutritional deficiencies and potential digestive or neurological issues, ongoing research is crucial for understanding and addressing these concerns.

The global weight loss drug market is experiencing explosive growth, with projections indicating a leap from $4.51 billion in 2023 to $22.85 billion by 2030, a CAGR of 26.1%. The market is expected to reach approximately $100 billion by 2030. The demand for weight loss solutions is escalating, with semaglutide-based products like Ozempic, Rybelsus, and Wegovy experiencing soaring sales. Notably, Wegovy's sales surged to $1.759 billion in the first half of 2024, marking a staggering 367% year-over-year increase.

Semaglutide's impact on the weight loss market is undeniable, offering a promising avenue for those seeking effective treatments for obesity and related conditions. As the market expands, the role of such medications in public health is set to become even more significant.

We Sinoway could supply semaglutide and its key intermediates, for details:

Semaglutide (CAS No.: 910463-68-2 ) * still in patent, so only for R&D use

Advantages:

1) Commercial production 10kg/month , 1kg in stock

2) With USDMF for Sermaglutide API.

3) Produced in GMP condition workshop, with:

Injection grade, purity 99% up by HPLC;

Oral grade, purity 98% up by HPLC

4) Competitive price compares with the original Novo Nordisk for API.

5) Using advanced recombinant protease with Bio-enzyme technology to produce the intermediates of Sermaglutide (main chain and side chain).

Semaglutide Intermediates:

(1) Main Chain: GLP-1 (9-37), CAS No.: 1169630-82-3, 95% up by HPLC

(2) Side Chain:

tBuO-Ste-Glu(AEEA-AEEA-OH-OtBu CAS No.: 1118767-16-0, 98% up by HPLC

Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEAI-OH CAS No.:1662688-20-1 , 98% up by HPLC

(3) Molecular Blocks

Octadecanedioic Acid Mono-tert-butyl Ester

CAS No.: 843666-40-0, 98% up by HPLC
AEEA-OH-HQ CAS No.: 134979-01-4, 98% up by HPLC
Fmoc-AEEA-OH CAS No.: 166108-71-0, 98% up by HPLC
Boc-AEEA-OH CAS No.: 108466-89-3, 98% up by HPLC
Fmoc-AEEA-AEEA-OH CAS No.: 560088-89-3, 98% up by HPLC
AEEA-AEEA-OH CAS No.: 1143516-05-5, 98% up by HPLC
Boc-Hs( Trt)-Aib-OH CAS No.: 2061897-68-3, 99% up by HPLC
Fmoc-Glu(OtBu)-Gly-OH CAS No.: 866044-63-5, 99.5% up by HPLC